JY
AVIR icon

Jeff Yass’s Atea Pharmaceuticals AVIR Stock Holding History

Jeff Yass’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$63.8K Sell
13,710
-68,125
-83% -$339K ﹤0.01% 12742
2026
Q1 		$440K Buy
81,835
+64,679
+377% +$297K ﹤0.01% 9987
2025
Q4 		$61.2K Sell
17,156
-32,538
-65% -$103K ﹤0.01% 11682
2025
Q3 		$144K Sell
49,694
-114,828
-70% -$392K ﹤0.01% 11311
2025
Q2 		$592K Buy
164,522
+58,938
+56% +$176K ﹤0.01% 8792
2025
Q1 		$316K Buy
105,584
+54,027
+105% +$169K ﹤0.01% 9959
2024
Q4 		$173K Sell
51,557
-1,611
-3% -$5.35K ﹤0.01% 10889
2024
Q3 		$178K Sell
53,168
-14,378
-21% -$52.1K ﹤0.01% 10578
2024
Q2 		$224K Sell
67,546
-117,865
-64% -$439K ﹤0.01% 10108
2024
Q1 		$749K Buy
185,411
+132,067
+248% +$517K ﹤0.01% 7558
2023
Q4 		$163K Sell
53,344
-164,530
-76% -$498K ﹤0.01% 10892
2023
Q3 		$654K Sell
217,874
-87,411
-29% -$297K ﹤0.01% 7608
2023
Q2 		$1.14M Buy
305,285
+119,828
+65% +$449K ﹤0.01% 6369
2023
Q1 		$621K Buy
185,457
+152,753
+467% +$620K ﹤0.01% 8034
2022
Q4 		$157K Buy
32,704
+11,484
+54% +$58.1K ﹤0.01% 10436
2022
Q3 		$121K Sell
21,220
-27,196
-56% -$208K ﹤0.01% 11503
2022
Q2 		$344K Buy
48,416
+5,807
+14% +$39.6K ﹤0.01% 9199
2022
Q1 		$308K Buy
42,609
+31,597
+287% +$215K ﹤0.01% 10209
2021
Q4 		$98K Sell
11,012
-67,325
-86% -$1.05M ﹤0.01% 12167
2021
Q3 		$2.75M Buy
78,337
+62,837
+405% +$1.74M ﹤0.01% 5138
2021
Q2 		$333K Buy
+15,500
New +$466K ﹤0.01% 10534

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jeff Yass's AVIR Position: Q2 2026 in Review

Jeff Yass reduced its Atea Pharmaceuticals (AVIR) stake by 83% in Q2 2026, selling an estimated $339K and leaving 13,710 shares worth $63.8K. The position accounts for ﹤0.01% of the portfolio, ranked #12742.

Jeff Yass first reported a position in AVIR in Q2 2021 and has held it in 21 quarters since. The position peaked at $2.75M in Q3 2021. 124 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Jeff Yass held 13,710 shares of Atea Pharmaceuticals worth $63.8K as of Q2 2026.
  • Jeff Yass sold 68,125 Atea Pharmaceuticals shares in Q2 2026, an estimated $339K.
  • Atea Pharmaceuticals made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12742 holding.
  • Jeff Yass first reported a position in Atea Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • Jeff Yass's Atea Pharmaceuticals position peaked at $2.75M in Q3 2021.
  • 124 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.